JP2023535842A - 普遍的な細胞療法のための武装ｎｋ細胞 - Google Patents

普遍的な細胞療法のための武装ｎｋ細胞 Download PDF

Info

Publication number
JP2023535842A
JP2023535842A JP2023507231A JP2023507231A JP2023535842A JP 2023535842 A JP2023535842 A JP 2023535842A JP 2023507231 A JP2023507231 A JP 2023507231A JP 2023507231 A JP2023507231 A JP 2023507231A JP 2023535842 A JP2023535842 A JP 2023535842A
Authority
JP
Japan
Prior art keywords
cells
domain
modified
region
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535842A5 (https=
Inventor
マルタン ヴィヤルバ
クリスチャン ヨルゲンセン
ブリュノ ロベール
ピエール マルティノー
フランシスコ ハビエル エルナンデス
ジェシー プレズミー
Original Assignee
ユニヴェルシテ ドゥ モンペリエ
アンスティトゥー ナショナル ドゥ ラ サンテ エ ドゥ ラ レシェルシュ メディカル（イエヌエスエエールエム）
サントル オスピタリエ ユニヴェルシテ ドゥ モンペリエ （セアッシュユエム）
イセエム（アンスティトゥー ドゥ キャンサロロジー ドゥ モンペリエ）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴェルシテ ドゥ モンペリエ, アンスティトゥー ナショナル ドゥ ラ サンテ エ ドゥ ラ レシェルシュ メディカル（イエヌエスエエールエム）, サントル オスピタリエ ユニヴェルシテ ドゥ モンペリエ （セアッシュユエム）, イセエム（アンスティトゥー ドゥ キャンサロロジー ドゥ モンペリエ） filed Critical ユニヴェルシテ ドゥ モンペリエ
Publication of JP2023535842A publication Critical patent/JP2023535842A/ja
Publication of JP2023535842A5 publication Critical patent/JP2023535842A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2023507231A 2020-07-31 2021-08-02 普遍的な細胞療法のための武装ｎｋ細胞 Pending JP2023535842A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2008211A FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation
FR2008211 2020-07-31
PCT/EP2021/071586 WO2022023581A1 (en) 2020-07-31 2021-08-02 Armed nk cells for universal cell therapy

Publications (2)

Publication Number Publication Date
JP2023535842A true JP2023535842A (ja) 2023-08-21
JP2023535842A5 JP2023535842A5 (https=) 2024-08-08

Family

ID=74095859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507231A Pending JP2023535842A (ja) 2020-07-31 2021-08-02 普遍的な細胞療法のための武装ｎｋ細胞

Country Status (9)

Country Link
US (1) US20240293455A1 (https=)
EP (1) EP4188396A1 (https=)
JP (1) JP2023535842A (https=)
KR (1) KR20230078632A (https=)
CN (1) CN116744946A (https=)
AU (1) AU2021316729A1 (https=)
CA (1) CA3189963A1 (https=)
FR (1) FR3112939B1 (https=)
WO (1) WO2022023581A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案
EP4729126A1 (en) 2024-10-17 2026-04-22 Centre National de la Recherche Scientifique Nk cell-derived extracellular vesicles armed with modified monoclonal antibodies to target cancer cells, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010525037A (ja) * 2007-04-25 2010-07-22 エルエフビー バイオテクノロジース 悪性病変、自己免疫性疾患、あるいは感染性疾患を治療するための部品キット
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Ｎｋ細胞の培養方法及びｎｋ細胞の利用
WO2018119288A1 (en) * 2016-12-22 2018-06-28 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US64413A (en) 1867-05-07 Improvement in wagon-beake
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1908395A (en) 1994-01-28 1995-08-15 Board Of Trustees Of The Leland Stanford Junior University Antibodies to mammalian natural killer antigens and uses
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US11753619B2 (en) * 2017-02-02 2023-09-12 The Scripps Research Institute Engineered cells and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010525037A (ja) * 2007-04-25 2010-07-22 エルエフビー バイオテクノロジース 悪性病変、自己免疫性疾患、あるいは感染性疾患を治療するための部品キット
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Ｎｋ細胞の培養方法及びｎｋ細胞の利用
WO2018119288A1 (en) * 2016-12-22 2018-06-28 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIEGO SANCHEZ-MARTINEZ ET AL.: ""Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multi", THERANOSTICS, vol. 8, no. 14, JPN6025020214, 2018, pages 3856 - 3869, ISSN: 0005597600 *
GREG A. LAZAR ET AL.: ""Engineered antibody Fc variants with enhanced effector function"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 11, JPN6025020216, 6 March 2006 (2006-03-06), pages 4005 - 4010, ISSN: 0005787470 *
KEVIN O. SAUNDERS: ""Conceptual Approaches toModulating Antibody Effector Functions and Circulation Half-Life"", FRONTIERS IN IMMUNOLOGY, vol. Vol. 10, Article 1296, JPN6025020215, 7 June 2019 (2019-06-07), pages 1 - 20, ISSN: 0005787471 *

Also Published As

Publication number Publication date
CA3189963A1 (en) 2022-02-03
FR3112939B1 (fr) 2024-01-05
US20240293455A1 (en) 2024-09-05
FR3112939A1 (fr) 2022-02-04
WO2022023581A1 (en) 2022-02-03
CN116744946A (zh) 2023-09-12
KR20230078632A (ko) 2023-06-02
EP4188396A1 (en) 2023-06-07
AU2021316729A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US12359002B2 (en) Heterodimeric antibodies that bind CD3 and tumor antigens
JP7695203B2 (ja) 操作されたｐｈ依存性抗ｃｄ３抗体、ならびにその作製方法および使用方法
US8569460B2 (en) Antibody constant domain regions and uses thereof
US20130344077A1 (en) Monoclonal antibodies
JP7774447B2 (ja) 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
JP2018519263A (ja) Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US20240293455A1 (en) Armed nk cells for universal cell therapy
US20250019439A1 (en) Anti-idiotype antibodies
EA049191B1 (ru) Универсальный продукт для клеточной терапии и его применение
EP4729126A1 (en) Nk cell-derived extracellular vesicles armed with modified monoclonal antibodies to target cancer cells, and use thereof
HK40102459A (zh) 用於通用细胞疗法的武装nk细胞
RU2831840C2 (ru) Высокоаффинные антитела к cd3 и способы их получения и применения
RU2832079C2 (ru) Сконструированные ph-зависимые антитела к cd3, а также способы их получения и применения
WO2025169945A1 (ja) 安定性が改善されたｃｄ３標的抗原結合分子
HK40093127A (zh) 结合cd3和肿瘤抗原的异二聚体抗体
HK40065611A (zh) 结合cd3和肿瘤抗原的异二聚体抗体

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260424